Drug
Pegylated Liposomal Mitoxantrone Hydrochloride clinical trials
Also written PLM60.
A product of Mitoxantrone; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
- PLM60
- 3
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Conjupro Biotherapeutics, Inc. (1)
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Mitoxantrone
Studies
Open first, then newest update. How each study uses Pegylated Liposomal Mitoxantrone Hydrochloride is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line ChemotherapyTerminatedPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04352413Written as PLM60
- A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCCStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04331743Written as Liposome-entrapped Mitoxantrone Hydrochloride Injection
- PLM60 for Peripheral T Cell Lymphoma (PTCL)WithdrawnPhase 1/2Conjupro Biotherapeutics, Inc.NCT03553914Written as PLM60